174 related articles for article (PubMed ID: 26886301)
1. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
[TBL] [Abstract][Full Text] [Related]
2. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance.
Stoeltzing O
Cell Cycle; 2010 Jun; 9(11):2051-2. PubMed ID: 20505332
[No Abstract] [Full Text] [Related]
4. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
8. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
12. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
13. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
Proia DA; Kaufmann GF
Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
15. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
16. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
19. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
Whitesell L; Lin NU
Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
[TBL] [Abstract][Full Text] [Related]
20. Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
Yuno A; Lee MJ; Lee S; Tomita Y; Rekhtman D; Moore B; Trepel JB
Methods Mol Biol; 2018; 1709():423-441. PubMed ID: 29177675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
